Jennifer Taubert, EVP, WW Chair, Pharmaceuticals at Johnson & Johnson (NYSE:JNJ), executed a sale of 59,397 shares in the company on February 9, 2024, according to a recent SEC filing. The shares were sold at an average price of $156.27, resulting in a total transaction amount of $9,282,677.19.
Johnson & Johnson is a global healthcare company that develops, manufactures, and sells a wide range of products in the healthcare field. Its operations are divided into three main segments: Consumer, Pharmaceutical, and Medical Devices. The company's portfolio includes well-known brands such as Tylenol, Neutrogena, and Band-Aid, as well as a robust drug pipeline in the pharmaceutical segment.
Over the past year, the insider has sold a total of 59,397 shares and has not made any purchases. The recent transaction is part of a series of sales by the insider, as indicated by the transaction history for Johnson & Johnson.
The insider transaction history for Johnson & Johnson shows a pattern of selling activity, with 0 insider buys and 5 insider sells over the past year.
On the valuation front, Johnson & Johnson's shares were trading at $156.27 on the day of the insider's sale, giving the company a market capitalization of $379,988.93 million. The price-earnings ratio stands at 13.03, which is below both the industry median of 22.125 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 0.82, with a GF Value of $190.65, suggesting that Johnson & Johnson is modestly undervalued according to GuruFocus's intrinsic value estimate.
The GF Value is determined by considering historical trading multiples such as price-earnings, price-sales, price-book, and price-to-free cash flow ratios, an adjustment factor based on the company's past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
